Undervalued Stocks in India

The earnings jump is real and operationally driven — the June-2026 quarter printed record revenue of about Rs 646 crore at a 14.2% EBITDA margin with no subsidy booked in the P&L — but its staying power rests on government ethanol allocations and grain prices that management itself says were partly exceptional in the… Consolidated EBITDA margin falls back below 8% for two consecutive quarters within FY27 (management's own breakeven logic says maize above ~Rs 24/kg or a DDGS collapse would do it), or the ethanol order book fails to…

ATUL has a strong recovered WHY: liquid epoxy resin capacity, product mix and improving group companies have already lifted results. Management has identified about ₹900 crore of sales from existing capacity, ₹600 crore from expansions and ₹300 crore initially from joint ventures. The recovery thesis fails if consolidated revenue growth drops below 5% for two quarters while EBITDA margin falls below 16%, or if the March 2027 power project slips without explanation.

The earnings rise is real and the mechanism is documented — tyre-cord volumes jumped after the GST cut and margins climbed on value-added mix, renewable power and pass-through pricing — but the latest 15% margin includes a disclosed one-time inventory gain of Rs 46.24 crore, and management themselves guide margins… Operating margin falls below 7% (the floor of management's own normalized range) for two consecutive quarters over the next two results — showing the Rs 46.24 crore inventory gain reversed without the value-added mix…

The earnings recovery is real and operationally proven — four straight quarters of margin expansion from cost cuts, full pass-through of the gas-shock price increases and rising factory utilization — but the newest quarter's 43% revenue jump is partly a one-off gain from the Morbi shutdown, so the test is whether… If the late-October 2026 Q2 FY27 call shows revenue falling back below roughly INR170 crore (the Morbi-shutdown windfall fully reversing) or EBITDA margin dropping below ~6% because gas normalised toward the pre-war…

The earnings rise is real — five straight quarters of margin recovery driven by volume growth, rising capacity utilisation and a nitrile-latex turnaround — but the Jun-26 spike to 22% OPM is partly war-driven price and inventory gain that management itself says is not the sustainable level (15-16%), so the durable… If the Sep-26 and Dec-26 quarters show OPM back below ~13% and revenue below ~400 crore, the 22% Jun-26 margin was a transient war-and-inventory spike, management's 15-16% average-margin claim fails, and the margin leg…

The earnings rise is real and operationally explained: four straight quarters of volume-led revenue growth plus A&P and opex leverage lifted EBITDA margin from 8.4% to a stated ~12% normalized in Q1 FY27, with negative working capital, Rs 83 crore of quarterly cash generation and a first-ever dividend backing the… Two consecutive quarters of normalized EBITDA margin below about 10% (excluding disclosed one-time items), or revenue growth decaying to single digits on the clean post-Flipkart base from Q2 FY27, would show the margin…

This is Batch C's best operating setup: tile volume, pricing, adjacencies and cost savings are all helping, but control failures and forecasting errors keep it below Tier A. Two quarters below 5% tile volume growth or 17% OPM, or another control failure.

The earnings rise is real and operationally explained — ADR-led RevPAR growth, a resort portfolio climbing from 43% toward 51% occupancy that is already lifting margins, and 85%-margin commercial rentals scaling from 245 to 290 million per month — but the 36x PE additionally assumes the large, previously-slipped… This read is wrong if, with the Powai porch in place (due end of Q2 FY27) and a full year of resort operations, hospitality EBITDA margin falls back below roughly 42% and resort occupancy stalls in the low-50s instead…

The earnings jump is real but is mostly a margin-recovery story, not a growth story: consolidated OPM went from a 3-9% trough in FY25 to a steady 16-17% over the last four quarters because management verifiably cut procurement costs, automated plants, exited loss-making die-casting contracts and over-delivered its own… This read is wrong if consolidated OPM slips back below 10% for two consecutive quarters, or if Lumel Alucast is still at negative adjusted EBITDA after March 2027 while EEI margin drops below 20% — that combination…

The earnings rise is real and volume-driven — Indian cage demand, recovering exports and new product lines, with segment numbers disclosed every quarter — but the promised margin kicker from Romania and Advantek turning profitable is still a promise, not yet a delivered result. If the Q2 FY27 results (due around November 2026) show the combined China+Romania loss annualizing above Rs 10 crore, Advantek still loss-making, and bushing growth under 20% YoY, then the 'PAT grows much faster than…

The earnings rise is real and well-explained: four calls in a row show segment-level revenue and margin chains (APS consolidation, wage pass-through, FM margin recovery from 4% to 5.5%) that the latest results confirm, but the profit line is noisy because two consecutive years took large one-off charges, and the… This read is wrong if a third large impairment lands in FY27, or if the consolidated EBITDA margin is still pinned at 4.5% or below by Q3 FY27 despite management's commitment that labour-code pass-through impact 'should…

The wind EPC curve and order book are real, but repeated order delays, a silently tripled IPP capital plan, a lower FY27 growth floor and weak H2 cash flow make management credibility a material risk. The case fails if order inflow stalls, OCF turns negative, or the March FY27 execution spike does not arrive.

The earnings rise is real: profit growth is driven by a genuinely fast-growing, fully secured gold-led loan book and credit cost halved to 0.8% — but the latest GNPA improvement is partly write-off-driven and the new RBI gold-loan rules will keep reported delinquencies optically elevated near term. Credit cost above 1% for two consecutive quarters in FY27, or Stage 2 staying above roughly 3% into Q3 FY27 while gold AUM growth drops below about 15% — that combination would show the post-regulatory delinquencies are…

The earnings rise is real — an exclusive, verified 70,000-unit Indonesia transfer case order plus rebuilt exports are flowing through reported revenue and margins — but the latest quarter's 29% EBITDA margin rests partly on a one-time tender that concludes within FY27, and the drivers meant to replace it in FY28 are… If, once the Indonesia contract completes (around end-FY27/early FY28), quarterly total income falls back toward Rs 90-100 crores with EBITDA margin near 20% and no revenue yet from the Japanese OEM transfer case, the…

The earnings rise is real and confirmed in reported results, but it is cost-led — margin expansion from the RIDF rundown and deposit repricing plus falling credit costs on a flat revenue base — and the open question is whether the new CEO's faster growth push converts it into genuine revenue growth without re-damaging… GNPA rising back above 2%, or the retail slippage ratio back above 4%, or NIM stalling at or below 2.7% through FY27 even as the RIDF rundown completes — any of these would say the cost-led profit machine has peaked and…

The earnings rise is real — four consecutive calls show segment-level revenue numbers matching management's volume, plant-occupancy and new-product-commercialisation story, and the latest quarter confirms it — but at roughly 73x earnings the price already assumes the next two years of guidance (25-30% growth, 20-22%… The thesis that this is a durable, guidance-delivering compounder is wrong if, by the Q2 and Q3 FY27 results (next check: late October 2026 call), quarterly EBITDA margin stays below 20% and Electrolyte Salts revenue…

The graph shows a genuine turnaround staircase: revenue 3056cr (FY22) to 5266cr (FY26) with OPM climbing 6% to 14%, PBT rising every single year (127 to 261cr), and cash conversion that is exceptional — 1368cr OCF against just 354cr PAT over FY24-26, with FCF positive all three years (1227cr cumulative) and zero… This read is wrong if D/E keeps climbing past ~1.6 over the next 2-3 years while OCF stalls below ~400cr, or if OPM falls back below 11% for two consecutive quarters, or if the Jun-2027 seasonal trough quarter prints…

Demand, orders and the capacity ramp are real, but the stock depends on policy-protected 29-30% margins surviving a large industry capacity wave. The high-quality growth read fails if EBITDA margin stays below 27% for two quarters or the new 7 GW cell line fails to reach 70% use by Q4 FY27.

The earnings rise is real and broad-based, but the heavy capacity build must now turn into cash without another debt or equity step-up. The bullish read fails if FY27 PAT misses Rs 200 crore while OCF stays below Rs 200 crore and borrowing still rises.

Hotel demand, occupancy and fixed-cost leverage are lifting profit sharply, but delayed projects and a large reset in the room target stop this from being top-tier. The case fails if there is no meaningful FY27 room-opening progress, or if occupancy falls below 70% or EBITDA margin below 35% for two quarters.

Revenue and profit are compounding through more products and acquisitions, but cash conversion and changing margin guidance keep the curve below top quality. The read fails if FY27 OCF remains negative and Dice does not lift consolidated margin by the second half.

The earnings rise is real, but the next jump depends on a debt-funded cell plant whose timing and revenue targets have already been cut. The thesis fails if the cell line misses Q4 FY27 or cannot reach 60% utilization within two quarters while debt rises above ₹1,500 crore.

The earnings rise is real but mostly a price event — sulphur-cost inflation passed straight through to customers plus inventory gains that management itself says will reverse — with the boron-business recovery and Latin America/China export substitution as the only structurally new profit drivers. If sulphur prices normalise over the next two quarters and DMCC's quarterly PAT falls back toward the Rs 6-11 crore run-rate while short-term borrowings remain elevated and operating cash flow stays negative, then the…

Premium fans, wires and cost savings are producing a real revenue and margin inflection, but gross-margin, working-capital and mix promises have not been consistently met. Revenue growth falls below 10% and EBITDA margin below 6% for two quarters.

This is a real bank turnaround: loan growth, funding mix and bad-loan cleanup all improved together, though some non-interest income and management targets need tighter checking. The turnaround fails if GNPA rises above 1.5%, slippage exceeds 0.5% annualized and NIM stays below 3.3%.

Gold loans and branch expansion are creating exceptional AUM and PAT growth, but rapid target changes, leadership changes and dilution require a lower credibility score. AUM growth falls below 25% while GNPA rises above 1.5%.

The margin rise is supported by premium mix and a larger order book, but the 30% growth target still requires delayed new products and project execution to arrive on time. The rerating case fails if WPC misses Q2 FY27, facade revenue misses Rs 40 crore and EBITDA margin drops below 18%.

Completed asset upgrades and higher room rates drove FY26, and management delivered its double-digit revenue promise. The next leg depends on RevPAR because there is no disclosed room-count growth, while Q1 FY27 consolidated PAT weakened and points to overseas-associate drag. The strong operating read fails if revenue growth drops below 5%, PBT margin falls below 15% or borrowings reverse above ₹150 crore.

The graph shows a classic commodity-chemical bust-and-recovery: annual PAT went 128 to -8 to -3 to 33 crore while OCF stayed positive every single year (84/56/92), so this business never bled cash even at the bottom of the cycle — the 1054% OCF/PAT ratio is a tiny-PAT artifact, not a red flag. This read is wrong if OPM falls back below 8% for two consecutive quarters over the next two quarters, or if the receivables build (debtor days 120, CCC 95) pushes operating cash flow negative in FY27 — that would say…

Protection growth and cost control are lifting VNB, but repeated explanation changes on persistency, commissions and the FY27 growth stance prevent this from being called clean qualitative proof. The case fails if protection slows sharply and VNB growth falls below 10% for two quarters while persistency worsens.

The graph shows cyclical repair, not structural growth: a FY23 boom (PAT 192cr, OPM 16%) crashed to 16cr PAT in FY24 and has climbed back to 48cr on only modestly higher revenue, with OPM hovering 9-11% and the newest quarter's 35cr PAT being a tax credit booked on zero PBT. This read is wrong if the margin recovery stalls: if OPM prints under 8% and quarterly PAT under 10cr for the next two quarters (Sep-26, Dec-26) — with the Jun-26 tax credit exposed as the only thing holding TTM EPS up…

The earnings rise is real and mechanistically explained — revenue, margin and working-capital guidance were set, repeated and then delivered with named operating drivers (MedTech mix, procurement scale, low-margin exits) — but the step-up to 50% EBITDA-to-operating-cash-flow conversion that the valuation depends on is… FY27 full-year operating cash flow below 50% of EBITDA (under roughly 130 crores) while the EBITDA margin holds at or above 5% — checkable at the March 2027 audited balance sheet, with an intermediate read at September…

The earnings rise is real but largely price-led, not volume-led: a war-driven doubling of ammonia cost was passed straight into finished-goods prices and lifted the latest quarter's margin, while the underlying business grew volumes only about 1% in FY26 — so the whole re-rating rests on whether the price stick holds… Quarterly operating margin falls back to the 18-19% pre-war range within the next two results (checkable by the concall expected around November 2026) as Rs 100+/kg ammonia flows fully through cost of materials — that…

The earnings rise is real at the operating level — signed long-term transit contracts, nine new cities and a genuine shift to direct advertisers lifted FY26 revenue 27% and EBITDA margin from 19.6% to 25.5% — but the profit is currently piling up in receivables (up about 80% year on year to roughly ₹317 crore) instead… If the December 2026 (Q3 FY27) results show receivable days still far above the 90-120 day range management committed to on the June 2026 call, alongside full-year OCF/PAT below roughly 45%, then the growth is accruing…

The growth engine and order book are real, but the equity is now a heavily leveraged power-asset bet and management credibility has weakened. The case fails if IPP capacity misses 1.6 GW by FY27-end or OCF/PAT falls below 40% while debt keeps rising.

AUM and profit are compounding near 30% with falling operating cost, but small-ticket stress and rising provisions make asset quality decisive. Two quarters above 1.6% credit cost with AUM growth below 20%.

New chemical capacity, richer materials mix and Fenesta growth can lift core earnings, but reported PAT is badly distorted by tax and asset-sale gains and management has changed project guidance often. Clean PAT fails to grow and ECH utilization does not improve by H2 FY27.

Sales, stores, old-gold exchange and diamond mix are all improving, but much of the FY26 margin spike came from gold-price gains and the business still consumes cash through inventory. Upgrade only if FY27 OCF turns positive and EBITDA margin stays at least 10% with flat-to-lower gold; downgrade if margin returns below 7.5% and PAT falls sharply.

The latest profit improvement is real because mix and cost discipline lifted margins even with lower sales, but TiO2 is impaired and management repeatedly predicted recoveries that did not arrive. The inflection fails if crop-protection margin falls below 15% before volume growth returns and pigment margin drops back below 8%.

The order book and factory ramp are real, but cash conversion worsened and management repeatedly changed growth and working-capital claims. The case fails if FY27 order conversion needs more debt while the cash cycle remains near 150 days.

Campaign growth, pricing and staff productivity kept FY26 EBITDA margin near 30%, but revenue growth slowed to 6.3% and user traffic fell in Q4. Management met the margin promise, missed its growth promises and did not deliver the stated capital return while cash rose to ₹5,852 crore. The operating thesis fails if revenue growth falls below 5% with paid campaigns flat or declining; the value thesis fails if excess cash is still not returned and is instead deployed into a low-return related-party…

The earnings rise is partly real — seven straight quarters of revenue growth driven by a genuine alkaline-battery premiumization shift that management has quantified and delivered on for two years — but the headline profit summit is one flattered quarter of land-sale income and a tax credit, and the promised… Two consecutive quarters (FY27-Q2 and Q3) of revenue growth above 10% YoY with OPM at or above 14% and zero exceptional items would prove the improvement is structural — alkaline mix plus Jammu operating leverage…

New chemical assets and captive power can add large profit, but commodity prices, other income and repeated capex/savings changes make the inflection cyclical and uncertain. New projects fail to add visible contribution by H2 FY27 while chemical margins fall.

Hotel pricing and upscale mix are real growth engines, but opening delays, changing cash-flow guidance and higher debt make the future curve less dependable than the demand story. The growth case weakens materially if same-store revenue growth falls below 9% and net-debt/EBITDA remains above 3x through FY28.

The earnings recovery is real in the filed numbers — the core alumina refractories segment's standalone result rose about a third year-on-year in the December 2025 quarter while the small power division's loss narrowed — but not a single management explanation of why exists anywhere in the evidence window, so the… This read is wrong if consolidated OPM falls back below 10% for two consecutive quarters (proving the Jun-26 print of 16.1% was a cyclical peak), or if the standalone refractories segment result falls back below roughly…

India's mix-led margin recovery is real, but Egypt and US conversion have slipped and management has repeatedly changed revenue and margin targets. The growth read fails if standalone margin falls below 15% for two quarters and Egypt still cannot hold 40% utilization.

Orders and margins are rising, but this remains a cash-hungry contractor with repeated numerical inconsistencies and reliance on debt for growth. The thesis fails if FY27 growth is funded by more debt without positive OCF or the PEB facility misses August 2026.

The earnings jump is real in the filed numbers — a newly commissioned LAB and HCD expansion, restarted after a planned Jan–Mar 2026 shutdown, plus recovering demand lifted Jun-2026 standalone revenue ~67% year on year with OPM near 15% — but it is proven by exactly one quarter, one press release and one filing note… If the September-2026 quarter (Q2 FY27 results, due around November 2026 on the NSE/BSE filings) shows revenue sliding back toward the old 450-460 crore run-rate or OPM below 10%, then the Jun-2026 spike was…

Productivity and pricing are improving, but headcount volatility, guidance cuts and other-income dependence make the PAT curve less durable than it looks. Headcount falls again and core EBITDA growth stays below 15%.

The Rajasthan and retail runway is visible, but slow collections, project delays and a one-off-heavy latest profit make the curve less powerful than it looks. The case fails if revenue growth stays below 10% for two more quarters or DSO rises above 160 days.

The June-2026 profit jump is real but mostly purchased rather than earned: roughly half the quarter's 158 crore revenue is the newly consolidated Netcom acquisition, the base business grew a modest 11.6%, and the AI margin lift management has promised for three straight calls has still not appeared in any number. This read is wrong if the September-2026 and December-2026 results show consolidated revenue falling back toward the standalone run-rate of about INR 61 crore a quarter (below roughly INR 120 crore), or consolidated…

The integrated workspace platform is growing, but repeated guidance cuts, dilution and debt make shareholder value much less certain than company-level growth. The case fails if share count does not freeze or FY27 seat/design growth misses the latest reduced targets.

The earnings rise is real in the reported numbers, but the latest quarter's surge is mostly a war-driven price premium on almost flat volumes, sitting on top of genuinely commissioned new capacity that has not yet contributed. This read is wrong if consolidated OPM falls back below 11% for two consecutive quarters (Q2 and Q3 FY27), showing the recovery was a transient war premium rather than a structural margin gain — or if the Egypt aseptic…

The earnings rise is real in the reported numbers and management gives a coherent, partly filing-corroborated explanation — a pivot to near-NPA-free medical insurance premium financing plus a 263 basis point fall in borrowing cost — but the forward story of a three-fold profit jump is still guidance, and after one… The pivot thesis is wrong if, by the Q3 FY27 call, GNPA is above 2.5% for two consecutive quarters, or the average borrowing cost is back above 12.5%, or quarterly PAT is still below roughly 20 crore — meaning the…